• +1-646-491-9876
    • +91-20-67278686

    Search

    Neuroblastoma-Pipeline Review H1 2017

    Neuroblastoma-Pipeline Review H1 2017

    • Report Code ID: RW0001834377
    • Category Pharmaceuticals
    • No. of Pages 417
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Neuroblastoma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Pipeline Review, H1 2017, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.

    Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 20, 19, 1, 44, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 6, 13 and 3 molecules, respectively.

    Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 5
    Neuroblastoma - Overview 6
    Neuroblastoma - Therapeutics Development 7
    Neuroblastoma - Therapeutics Assessment 23
    Neuroblastoma - Companies Involved in Therapeutics Development 37
    Neuroblastoma - Drug Profiles 64
    Neuroblastoma - Dormant Projects 390
    Neuroblastoma - Discontinued Products 393
    Neuroblastoma - Product Development Milestones 394
    Appendix 404

    List of Tables

    Number of Products under Development for Neuroblastoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, H1 2017
    Neuroblastoma - Pipeline by Actuate Therapeutics Inc, H1 2017
    Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, H1 2017
    Neuroblastoma - Pipeline by Alissa Pharma, H1 2017
    Neuroblastoma - Pipeline by Ampio Pharmaceuticals Inc, H1 2017
    Neuroblastoma - Pipeline by APAvadis Biotechnologies Srl, H1 2017
    Neuroblastoma - Pipeline by APEIRON Biologics AG, H1 2017
    Neuroblastoma - Pipeline by AstraZeneca Plc, H1 2017
    Neuroblastoma - Pipeline by Bayer AG, H1 2017
    Neuroblastoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
    Neuroblastoma - Pipeline by Bexion Pharmaceuticals LLC, H1 2017
    Neuroblastoma - Pipeline by BioLineRx Ltd, H1 2017
    Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H1 2017
    Neuroblastoma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Neuroblastoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Neuroblastoma - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017
    Neuroblastoma - Pipeline by Cebiotex SL, H1 2017
    Neuroblastoma - Pipeline by Celgene Corp, H1 2017
    Neuroblastoma - Pipeline by Celldex Therapeutics Inc, H1 2017
    Neuroblastoma - Pipeline by Cielo Therapeutics Inc, H1 2017
    Neuroblastoma - Pipeline by Cleveland BioLabs Inc, H1 2017
    Neuroblastoma - Pipeline by CorMedix Inc, H1 2017
    Neuroblastoma - Pipeline by Curis Inc, H1 2017
    Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
    Neuroblastoma - Pipeline by DEKK-TEC Inc, H1 2017
    Neuroblastoma - Pipeline by EnGeneIC Ltd, H1 2017
    Neuroblastoma - Pipeline by Errant Gene Therapeutics LLC, H1 2017
    Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H1 2017
    Neuroblastoma - Pipeline by Green Cross Cell Corp, H1 2017
    Neuroblastoma - Pipeline by Ignyta Inc, H1 2017
    Neuroblastoma - Pipeline by Juno Therapeutics Inc, H1 2017
    Neuroblastoma - Pipeline by Lindis Biotech GmbH, H1 2017
    Neuroblastoma - Pipeline by MabVax Therapeutics Holdings Inc, H1 2017
    Neuroblastoma - Pipeline by MacroGenics Inc, H1 2017
    Neuroblastoma - Pipeline by MediaPharma srl, H1 2017
    Neuroblastoma - Pipeline by Merck & Co Inc, H1 2017
    Neuroblastoma - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
    Neuroblastoma - Pipeline by Morphogenesis Inc, H1 2017
    Neuroblastoma - Pipeline by Novartis AG, H1 2017
    Neuroblastoma - Pipeline by Novogen Ltd, H1 2017
    Neuroblastoma - Pipeline by OGD2 Pharma SAS, H1 2017
    Neuroblastoma - Pipeline by Pfizer Inc, H1 2017
    Neuroblastoma - Pipeline by Phylogica Ltd, H1 2017
    Neuroblastoma - Pipeline by Progenics Pharmaceuticals Inc, H1 2017
    Neuroblastoma - Pipeline by Recombio SL, H1 2017
    Neuroblastoma - Pipeline by Ribomic Inc, H1 2017
    Neuroblastoma - Pipeline by Sapience Therapeutics Inc, H1 2017
    Neuroblastoma - Pipeline by Sareum Holdings Plc, H1 2017
    Neuroblastoma - Pipeline by Shionogi & Co Ltd, H1 2017
    Neuroblastoma - Pipeline by Sierra Oncology Inc, H1 2017
    Neuroblastoma - Pipeline by Syros Pharmaceuticals Inc, H1 2017
    Neuroblastoma - Pipeline by Tiltan Pharma Ltd, H1 2017
    Neuroblastoma - Pipeline by Trovagene Inc, H1 2017
    Neuroblastoma - Dormant Projects, H1 2017
    Neuroblastoma - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Neuroblastoma - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Neuroblastoma - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Neuroblastoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Ability Pharmaceuticals SL
    Actuate Therapeutics Inc
    Advanced Accelerator Applications SA
    Alissa Pharma
    Ampio Pharmaceuticals Inc
    APAvadis Biotechnologies Srl
    APEIRON Biologics AG
    AstraZeneca Plc
    Bayer AG
    Bellicum Pharmaceuticals Inc
    Bexion Pharmaceuticals LLC
    BioLineRx Ltd
    Biotec Pharmacon ASA
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Cancer Prevention Pharmaceuticals Inc
    Cebiotex SL
    Celgene Corp
    Celldex Therapeutics Inc
    Cielo Therapeutics Inc
    Cleveland BioLabs Inc
    CorMedix Inc
    Curis Inc
    Cyclacel Pharmaceuticals Inc
    DEKK-TEC Inc
    EnGeneIC Ltd
    Errant Gene Therapeutics LLC
    F. Hoffmann-La Roche Ltd
    GlaxoSmithKline Plc
    Green Cross Cell Corp
    Ignyta Inc
    Juno Therapeutics Inc
    Lindis Biotech GmbH
    MabVax Therapeutics Holdings Inc
    MacroGenics Inc
    MediaPharma srl
    Merck & Co Inc
    Merrimack Pharmaceuticals Inc
    Morphogenesis Inc
    Novartis AG
    Novogen Ltd
    OGD2 Pharma SAS
    Pfizer Inc
    Phylogica Ltd
    Progenics Pharmaceuticals Inc
    Recombio SL
    Ribomic Inc
    Sapience Therapeutics Inc
    Sareum Holdings Plc
    Shionogi & Co Ltd
    Sierra Oncology Inc
    Syros Pharmaceuticals Inc
    Tiltan Pharma Ltd
    Trovagene Inc

    Request for Sample

    Report Url https://www.reportsweb.com//neuroblastoma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//neuroblastoma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//neuroblastoma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments